Baseline characteristics were similar (CDDP+S-1/CDDP+PEM): median age (range) 64.5 (39-73)/63.5 (32-74) years; women, n=17 (33%)/n=17 (34%); stage IIIB, n=21 (40%)/n=20 (40%); ECOG PS of 1, n=14 (27%)/n=14 (28%); never smoker, n=12 (23%)/n=12 (24%);...
Background To assess the safety and efficacy of vitamin B12 and folic acid starting 24 to 48 hours before the chemotherapy including pemetrexed (PEM). Methods Patients with advanced non-squamous non-small cell lung cancer or malignant pl... S Kitagawa,K Watanabe,Y Takagi,... - 《Annals of...
P3.02b-087 Dose Escalation Study of CDDP plus PEM with Erlotinib and Bev Followed by PEM with Erlotinib and Bev for Non-SQ NSCLC Harboring EGFR MutationsGefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced non-small cell ...
OA12.02 Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with Thoracic RT for Locally Advanced Non-Sq NSCLC: SPECTRA Studydoi:10.1016/j.jtho.2019.08.472T. SetoS. NihoT. YoshidaT. AkimotoY. OheJournal of Thoracic Oncology
P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)doi:10.1016/j.jtho.2018.08.589Harada, T.Udagawa, H.Sugiyama, E.Atagi, S.Koyama, R.Watanabe, S.
P3.01-90 A Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bevdoi:10.1016/j.jtho.2018.08.1650S. ShojiS. WatanabeK. NozakiK. IchikawaT. KikuchiJournal of Thoracic Oncology...